featured
Efficacy and Safety of Treatment With Odevixibat in Patients With Alagille Syndrome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Gastroenterology & Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial
Lancet Gastroenterol Hepatol 2024 Jul 01;9(7)632-645, N Ovchinsky, M Aumar, A Baker, U Baumann, P Bufler, M Cananzi, P Czubkowski, Ö Durmaz, R Fischer, G Indolfi, WW Karnsakul, F Lacaille, WS Lee, G Maggiore, P Rosenthal, M Ruiz, E Sokal, E Sturm, W van der Woerd, HJ Verkade, A Wehrman, C Clemson, Q Yu, Q Ni, J Ruvido, S Manganaro, JP MattssonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.